Month: July 2024

Food Prep Tables Market to Expand at 5.39% CAGR, Hitting $1.62 Billion Revenue by 2029 – Arizton Advisory & Intelligence

“Food Prep Tables Market”
The emergence of smart & connected tables, demand for multi-purpose food prep tables, and emphasis on customization & modularity are significant trends in the market.

According to the latest research report titled, the food prep tables market – global outlook & forecast 2024-2029 by Arizton Advisory & Intelligence, it will grow at a CAGR of 5.39% during 2023-2029.    

To Know More, Click: https://www.arizton.com/market-reports/food-prep-tables-market 

The global food prep table market is poised for continued growth and innovation as the food service industry evolves to meet the changing demands of consumers worldwide. With urbanization, globalization, and technological advances driving transformation across the food service landscape, manufacturers of food prep tables will need to stay agile and responsive to emerging trends and customer preferences to maintain a competitive edge in the market. Moreover, collaboration and partnerships between industry players, technology providers, and regulatory bodies will be critical in fostering innovation and advancing standards for food safety, sustainability, and operational excellence in commercial kitchens globally. By leveraging these opportunities and addressing evolving market needs, players in the food prep table market can position themselves for sustainable growth and success. 

Report Summary  

Market Size (2029): USD 1.62 Billion 

Market Size (2023): USD 1.18 Billion 

CAGR (2023-2029): 5.39% 

Historic Year: 2020-2022 

Base Year: 2023 

Forecast Year: 2024-2029 

Market Segmentation: Material, End-User, Distribution Channel, And Geography 

Geographical Analysis: North America, Europe, Apac, Latin America, And Middle East & Africa 

Stay ahead of the curve with Arizton’s exclusive subscription plan, offering in-depth analysis, market sizing, and growth forecasts for less than $900 per month—a significant value compared to individual report purchases. Click here: https://www.arizton.com/subscription   

Market Development 

Hoshizaki Corporation focuses on strengthening product supply and position in the global market. In March 2024, the company acquired 51% of the shares of a Turkish food service equipment manufacturer, Öztriyakiler Madeni Esya Sanayi ve Ticaret Anonim Sirketi, establishing it as a subsidiary. 

Online Distribution Channel to Create Buzz in the Market  

The adoption of online channels, particularly through e-commerce platforms, has significantly transformed the distribution of food prep tables and related kitchen equipment. Major players like Amazon, eBay, and Alibaba offer vast selections, enabling customers to compare prices and read reviews easily. Specialty e-commerce stores cater to niche needs, providing curated selections and expert advice. Direct sales from manufacturers via online stores offer detailed product information and support, fostering brand loyalty. 

Brick-and-click retailers combine physical stores with online platforms, offering omnichannel experiences such as in-store pickup. Subscription services provide recurring shipments, appealing to regular users and ensuring steady revenue. Social media platforms, through social commerce and influencer marketing, drive sales by showcasing products visually and enabling direct purchasing from feeds. 

Auctions and classifieds provide avenues for competitive pricing and local/national sales of both new and used items. Review and comparison websites play a crucial role by aggregating reviews and facilitating price comparisons, empowering customers to make informed decisions. Overall, the online distribution landscape for food prep tables is diverse and dynamic, accommodating various consumer preferences and enhancing accessibility and convenience. 

Investment in APAC is Expected to Lead to Market Expansion 

Changing consumer lifestyles and dining habits have shaped APAC’s demand for food prep tables. Rapid urbanization, busy lifestyles, and the growing trend of eating out have driven demand for convenient and efficient foodservice solutions. Food prep tables that offer versatility, customization options, and space-saving features are particularly popular among foodservice operators in urban areas, where space constraints are common. The growing popularity of food delivery and online ordering in APAC countries encourages more individuals to launch cloud kitchens. The increase in cloud kitchens in the region is expected to increase the need for food prep tables. Therefore, this shifting consumer preference is projected to boost the demand for prep tables, which are highly needed for efficient food preparation and storage setups.  

Top Companies Featured in Our Report  

  • Ali Group 

  • Hoshizaki Corporation 

  • True Manufacturing 

  • Turbo Air 

  • AyrKing 

  • Cambro 

  • Continental Refrigerator 

  • Crystal 

  • Duke Manufacturing 

  • Electrolux Professional 

  • Everest Refrigeration 

  • Fagor Industrial 

  • Grupo Infrico 

  • Ilsa 

  • KDM Steel 

  • Mercatus 

  • Stalgast 

  • The Vollrath Company 

  • Traulsen (ITW Food Equipment Group) 

Market Segmentation 

Material 

  • Steel 

  • Composite 

End-user 

  • Restaurants 

  • Hotels 

  • Others 

Distribution Channel 

  • Offline 

  • Online 

Geography 

  • North America 

  • The US 

  • Canada 

  • APAC 

  • China 

  • India 

  • Japan 

  • Indonesia 

  • Australia 

  • South Korea 

  • Thailand 

  • Europe 

  • France 

  • Italy 

  • Spain 

  • The UK 

  • Germany 

  • Poland 

  • Netherlands 

  • Middle East & Africa 

  • The UAE 

  • Saudi Arabia 

  • South Africa 

  • Latin America 

  • Brazil 

  • Mexico 

  • Argentina 

Explore Our Top-Selling Research Reports: 

U.S. Contract Catering Market – Industry Analysis & Forecast 2023-2028 

https://www.arizton.com/market-reports/us-contract-catering-market 

Robot Waiter Market – Global Outlook & Forecast 2023-2028 

https://www.arizton.com/market-reports/robot-waiter-market 

Why Arizton?                           

100% Customer Satisfaction                           

24×7 availability – we are always there when you need us                           

200+ Fortune 500 Companies trust Arizton’s report                           

80% of our reports are exclusive and first in the industry                           

100% more data and analysis                           

1500+ reports published till date          

Post-Purchase Benefit                       

  • 1hr of free analyst discussion                       

  • 10% off on customization    

About Us:                                                                

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                              

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                               

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                     

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040  
Country: United States
Website: https://www.arizton.com/market-reports/food-prep-tables-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Food Prep Tables Market to Expand at 5.39% CAGR, Hitting $1.62 Billion Revenue by 2029 – Arizton Advisory & Intelligence

Polyester Fiber Market Analysis, Trends, Share, Opportunities, Key Segmentation, Regional Growth, Top Companies, and Forecast to 2028

“Browse 190 market data Tables and 53 Figures spread through 243 Pages and in-depth TOC on “Polyester Fiber Market””
The Polyester Fiber Market is thriving due to its versatility in textiles and non-woven applications. Asia-Pacific dominates production and consumption, driven by robust demand in apparel, home furnishings, and automotive sectors.

The global polyester fiber market is expected to be USD 102.2 billion in 2023 and is projected to reach USD 151.6 billion by 2028, at a CAGR of 8.2% from 2023 to 2028. Demand for polyester fiber is rising across a range of applications, including automotive, textile, and home furnishing, among others. Additionally, the recyclability of polyester fiber has increased demand for polyester fiber in recent years. 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=140971799  

Based on the application, the market has been divided into several applications, such as textile & apparel, home furnishing, automotive & transportation and others. Polyester fiber’s versatility and range of properties make it suitable for a broad spectrum of applications, from fashion and home textiles to industrial and technical uses. Its resistance to moisture, durability, and ease of maintenance make it a reliable choice in various industries. The textile & apparel is predicted to dominate these applications in the global polyester fiber market. This dominance of polyester fiber in the textile industry is due to its wrinkle resistance, color retention, and quick-drying properties. 

Based on the form, the polyester fiber market is segmented into two categories based on form which are solid and hollow. The solid polyester fiber is expected to lead the market and is ezpected to witnessed a surge in demand, accompanied by an impressive Compound Annual Growth Rate (CAGR), owing to its exceptional versatility and remarkable properties. Its ease of maintenance and cleaning makes it a preferred choice for home furnishings, carpets, and upholstery. Solid polyester fiber is a popular choice because of its durability and resilience, withstanding the test of time and wear, a feature highly prized in products that require longevity and strength. 

Based on the grade, there are two grades of polyester fiber considered in the report namely PET polyester fiber and PCDT polyester fiber. PET polyester fiber segment lead the global polyester fiber market and is also expected to witness a high CAGR compared to PCDT polyester fiber. PET polyester fiber’s affordability, robustness, and adaptability are the reasons behind its broad appeal. It is extensively utilized in a variety of industrial applications, clothing, and textiles. PET polyester is a popular option for many applications because it combines strength, resistance to deterioration, and resilience to environmental elements. Additionally, PET polyester fiber is highly recyclable and suitable for use in sustainable and eco-friendly applications, which is in line with the increasing emphasis on environmental conservation around the world. In contrast, the broader market growth of PCDT polyester fiber is impeded by its more restricted range of applications, despite its possession of certain desired qualities. 

Based on product type, there are two types of polyester fibers polyester filament yarn and polyester staple fiber. Because of its adaptability and use in a variety of applications, such as textiles, clothing, home furnishings, industrial purposes, and technical applications, polyester fiber yarn is highly sought after. Its strength, resilience to many weather conditions, and durability make it extremely valuable due to this reason polyester filament yarn is expected to witness the higher CAGR. 

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=140971799 

Based on region, From 2023 to 2028, the polyester fiber market is projected to grow with the highest compound annual growth rate (CAGR) in the Asia Pacific region. China accounted for the largest market share of the Asia Pacific polyester fiber market in 2022. Due to the considerable and fast growing population in the region, there is a greater need for apparel, textiles, and home furnishings many of which are made of polyester fiber and consumer spending has surged as a result. This demand is largely driven by the textile and garment industry in the Asia-Pacific region, which is well-known for its manufacturing prowess. Furthermore, the growth of the middle class in nations like China and India has increased disposable money, which has led to a spike in the market for goods made of polyester fibers. In addition, the region’s impressive economic expansion has supported the growing demand for polyester fibers in a variety of industries, including automotive and construction, along with the development of industrial applications and infrastructure. 

Major players operating in the polyester fiber market include Zhejiang Hengyi Group Co., Ltd. (China), Reliance Industries Ltd. (India), Indorama Venture  Public Company Ltd. (Thailand), Toray Industries Ltd. (Japan), Sinopec Yizheng Chemical Fiber Limited Liablity Company (China), Alpek S.A.B DE C.V. (Mexico), Diyou Fiber (M) Sdn Bhd (Malaysia), Bombay Dyeing (India), and Green Group SA (Romania). These companies have their reliable manufacturing plants and well-established distribution networks that reach across key areas like North America, Europe, and the Asia Pacific. They have a well-known range of top-notch goods and services, a commanding market presence, and solid business plans. Additionally, these businesses control a sizeable portion of the market, provide goods with a variety of uses, serve a large geographic area, and maintain a vast variety of items.

Request Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=140971799 

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/polyester-fiber-market-140971799.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Polyester Fiber Market Analysis, Trends, Share, Opportunities, Key Segmentation, Regional Growth, Top Companies, and Forecast to 2028

Diffuse Large B-Cell Lymphoma Pipeline 2024 | Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Otsuka, OncoNano, Hoffmann-L

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Explore our latest breakthroughs in Diffuse Large B-Cell Lymphoma Research. Learn more about our innovative pipeline today! @ Diffuse Large B-Cell Lymphoma Pipeline Outlook

 Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report

  • June 2024:- Incyte Corporation– The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).
  • June 2024:- Dana-Farber Cancer Institute– A Phase I/II Study of Copanlisib Plus Venetoclax for the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma. This study is an open-label, multi-center, non-randomized phase I/II study of the combination treatment copanlisib + venetoclax in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
  • June 2024:- Genmab– The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.
  • June 2024:- Pfizer– The purpose of this study is to learn about the effects of two study medicines (maplirpacept [PF-07901801] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed means has returned after last treatment. Refractory means that it has not responded to last treatment. The two study medicines are given after a single dose of obinutuzumab which is the third study medicine.
  • DelveInsight’s Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Metastatic Prostate Cancer treatment.
  • The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutics, Otsuka Pharmaceutical, OncoNano Medicine Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others.
  • Promising Diffuse Large B-Cell Lymphoma Therapies such as R-miniCHOP + Acalabrutinib, Selinexor, Tafasitamab, Lenalidomide, and others. 

Stay informed about the cutting-edge advancements in Diffuse Large B-Cell Lymphoma treatments. Download for updates and be a part of the revolution in cancer care @ Diffuse Large B-Cell Lymphoma Clinical Trials Assessment 

Diffuse Large B-Cell Lymphoma Emerging Drugs Profile

  • Brentuximab vedotin: Pfizer

Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

  • THOR-707: Sanofi

THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

  • Abexinostat: Xynomic Pharmaceuticals

Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma.

  • RNK05047: Ranok Therapeutics

RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok’s proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints.

  • BMF-219: Biomea Fusion

BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

  • ADI-001: Adicet Bio

ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. 

Learn more about Diffuse Large B-Cell Lymphoma Drugs Opportunities in our groundbreaking Diffuse Large B-Cell Lymphoma research and development projects @ Diffuse Large B-Cell Lymphoma Unmet Needs 

Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical 

Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Diffuse Large B-Cell Lymphoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives 

Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report

  • Coverage- Global
  • Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutics, Otsuka Pharmaceutical, OncoNano Medicine Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others.
  • Diffuse Large B-Cell Lymphoma Therapies- R-miniCHOP + Acalabrutinib, Selinexor, Tafasitamab, Lenalidomide, and others.
  • Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III 

For a detailed overview of our latest research findings and future plans, read the full details of Diffuse Large B-Cell Lymphoma pipeline on our website @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Companies 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Diffuse Large B-Cell Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Diffuse Large B-Cell Lymphoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Brentuximab vedotin: Pfizer
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. THOR-707: Sanofi
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ADI-001: Adicet Bio
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Diffuse Large B-Cell Lymphoma Key Companies
  21. Diffuse Large B-Cell Lymphoma Key Products
  22. Diffuse Large B-Cell Lymphoma- Unmet Needs
  23. Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
  24. Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
  25. Diffuse Large B-Cell Lymphoma Analyst Views
  26. Diffuse Large B-Cell Lymphoma Key Companies
  27. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diffuse Large B-Cell Lymphoma Pipeline 2024 | Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Otsuka, OncoNano, Hoffmann-L

Esophageal Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co.

DelveInsight’s, “Esophageal Squamous Cell Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Esophageal Squamous Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Esophageal Squamous Cell Carcinoma Pipeline Outlook

Key Takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report

  • June 2024:- Sichuan Baili Pharmaceuticals- Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 Combined With Irinotecan in the Treatment of Recurrent and Metastatic Esophageal Squamous Cell Carcinoma. This multi-center, open label Phase II clinical study is performed in patients with relapsed and metastatic esophageal squamous cell carcinoma progressed on prior PD-1/L1 antibody with or without chemotherapy. This study is investigating the safety and efficacy of SI-B001 at optimal combination dose with irinotecan in patients.
  • DelveInsight’s Esophageal Squamous Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Esophageal Squamous Cell Carcinoma treatment.
  • The leading Esophageal Squamous Cell Carcinoma Companies such as BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
  • Promising Esophageal Squamous Cell Carcinoma Therapies such as Camrelizumab, SI-B001, Irinotecan, Paclitaxel, Cisplatin, JMT101, and others.

Stay informed about the cutting-edge advancements in Esophageal Squamous Cell Carcinoma Treatments. Download for updates and be a part of the revolution in oncology care @ Esophageal Squamous Cell Carcinoma Clinical Trials Assessment

Esophageal Squamous Cell Carcinoma Emerging Drugs Profile

  • Tislelizumab: BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene’s immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Currently, it is in Phase III stage of clinical trial evaluation to treat Esophageal Squamous Cell Carcinoma.

  • Serplulimab: Shanghai Henlius Biotech

Serplulimab (novel anti-PD-1 mAb) is the first innovative monoclonal antibody (mAb) developed by Henlius. Shanghai Henlius Biotech, announced that the phase 3 clinical study ASTRUM-007 of HANSIZHUANG (serplulimab) independently developed by the company in combination with chemotherapy as a first-line treatment for patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC), met the co-primary endpoints of progression-free survival (PFS) and overall survival (OS) in a planned interim analysis, evaluated by the Independent Data Monitoring Committee (IDMC).

Learn more about Esophageal Squamous Cell Carcinoma Drugs opportunities in our groundbreaking Esophageal Squamous Cell Carcinoma Research and development projects @ Esophageal Squamous Cell Carcinoma Unmet Needs

Esophageal Squamous Cell Carcinoma Companies

BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.

Esophageal Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

Esophageal Squamous Cell Carcinoma Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

Discover the latest advancements in Esophageal Squamous Cell Carcinoma Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology disease @ Esophageal Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Esophageal Squamous Cell Carcinoma Companies- BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
  • Esophageal Squamous Cell Carcinoma Therapies- Camrelizumab, SI-B001, Irinotecan, Paclitaxel, Cisplatin, JMT101, and others.
  • Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Esophageal Squamous Cell Carcinoma Pipeline on our website @ Esophageal Squamous Cell Carcinoma Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Esophageal Squamous Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Esophageal Squamous Cell Carcinoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Tislelizumab: BeiGene
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. RAPA-201: Rapa Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. SGN-B6A: Seagen
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Esophageal Squamous Cell Carcinoma Key Companies
  21. Esophageal Squamous Cell Carcinoma Key Products
  22. Esophageal Squamous Cell Carcinoma- Unmet Needs
  23. Esophageal Squamous Cell Carcinoma- Market Drivers and Barriers
  24. Esophageal Squamous Cell Carcinoma- Future Perspectives and Conclusion
  25. Esophageal Squamous Cell Carcinoma Analyst Views
  26. Esophageal Squamous Cell Carcinoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Esophageal Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co.

Thymidylate Synthase Inhibitor Market is Riding on the Wave of Growth – Here’s Why

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Thymidylate Synthase Inhibitor Market – (By Type (Injection, Tablet, Others), By Application (Hospital, Clinic, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”

According to the latest research by InsightAce Analytic, the Global Thymidylate Synthase Inhibitor Market is predicted to grow with a CAGR of 6.0% during the forecast period of 2024-2031.

 

Download Free Report Sample Pages: https://www.insightaceanalytic.com/request-sample/2549

 

Thymidylate synthase inhibitors are a group of drugs that stop the enzyme thymidylate synthase from working. This enzyme is important for making DNA and copying cells. The market for thymidylate synthase inhibitor medications is expected to grow due to an increase in healthcare spending and a surge in pipeline studies. The market growth rate would be positively affected by other variables, such as changing lifestyles and increased awareness. The thymidylate synthase inhibitor pharmaceuticals market is expected to have rapid expansion in the next years, driven by factors such as improved medical technology, increased government financing, and rising disposable incomes.

In addition, the use of thymidylate synthase inhibitors is supported by clinical data that shows better patient outcomes and survival rates. More of these treatments are needed because older people are more likely to get cancer. Growth in the market is also helped by regulatory approvals and rising healthcare costs, especially in emerging areas. Market expansion will be hindered in low-income nations due to infrastructure issues and the high cost of medications. The thymidylate synthase inhibitor market is expected to have substantial revenue growth during the projected period due to industry participants’ development and the introduction of more innovative inhibitor products. 

List of Prominent Players in the Thymidylate Synthase Inhibitor Market:

  • Teva Pharmaceutical
  • Fresenius Kabi
  • Cadila Pharmaceuticals
  • Eli Lilly
  • Novartis
  • Amgen
  • AstraZeneca
  • Sanofi
  • Bristol-Myers Squibb
  • Merck & Co
  • AbbVie
  • Roche
  • Johnson & Johnson
  • Viatris
  • Abbott
  • Pfizer
  • Accord Healthcare
  • GlaxoSmithKline
  • Sun Pharmaceutical
  • Bayer
  • Baxter 

Market Dynamics: 

Drivers-

The global market for thymidylate synthase inhibitors is being driven by the rising number of cancer cases that need effective chemotherapy treatments to maintain and control tumour growth. As studies in oncology move forward, new and stronger thymidylate synthase inhibitors are always being made, which increases their therapeutic potential and effectiveness. Combining these inhibitors with other anticancer drugs makes them even more effective, which leads to better patient results and higher adoption rates. The market for thymidylate synthase inhibitors is also rising in the coming years because more people are learning about personalized medicine and targeted therapies. 

Challenges:

The thymidylate synthase inhibitors market is slowing growth due to some issues, such as the high prices of developing and making thymidylate synthase inhibitors, which make them hard to get and expensive, especially in developing countries where money for healthcare is tight.  Because of these prices, smaller drug companies do not want to put money into researching and developing these inhibitors. Moreover, the fact that thymidylate synthase inhibitors can cause serious side effects and poisoning is a big challenge. These effects can make healthcare workers and patients hesitant to use the treatment, and they choose other treatments with better safety profiles instead. Some of these factors can slow the market’s growth. 

Regional Trends:

The North American thymidylate synthase inhibitor market is anticipated to report a major market revenue share. It is projected to grow at a high CAGR in the near future because the presence of the world’s leading businesses engaged in pharmaceutical and synthase inhibitors, the region’s excellent healthcare system, and high disposable income are key drivers propelling market progress in the area over the predicted period. Besides, Europe had a remarkable share in the market because of more products being approved, more people being aware of their existence, the rising tide of chronic diseases, more government funding, and more R&D efforts in this area. In addition, the number of major market players and big players are working together more to get into new markets in these areas, which is good for the global thymidylate synthase inhibitor market.

 

Curious About This Latest Version Of The Report? Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/2549 

 

Segmentation of Thymidylate Synthase Inhibitor Market-

By Type-

  • Injection
  • Tablet
  • Others

By Application-

  • Hospital
  • Clinic
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Media Contact
Company Name: InsightAce Analytic Pvt. Ltd
Contact Person: Diana D’Souza
Email: Send Email
Country: United States
Website: https://www.insightaceanalytic.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thymidylate Synthase Inhibitor Market is Riding on the Wave of Growth – Here\’s Why

Composites Market Size, Opportunities, Top Companies, Growth, Trends, Regional Analysis, Key Segments, and Forecast to 2028

“Browse 487 market data Tables and 97 Figures spread through 499 Pages and in-depth TOC on “Composites Market””
The Composites Market is rapidly growing, driven by high demand in aerospace, automotive, and construction sectors. Advancements in materials like carbon and glass fibers offer superior strength, weight reduction, and durability. North America and Asia-Pacific lead regional growth.

The global composite market size was valued at approximately USD 108.8 billion in 2023 and is expected to reach to reach USD 181.7 billion by 2028, projecting a CAGR of 10.8%  during the forecast period between 2023 and 2028. A composite material is a mixture of two different materials with different properties, such as mechanical, micro-cracking, and fatigue resistance, remarkable tensile strength, electrical conductivity, and high strength-to-weight ratio, which, when combined, offers an end-product with superior properties. Composites are composed of reinforcement fibers bound together by polymer matrix resins. Various fibers (glass, carbon, natural, and others) and polymer matrix (thermoset and thermoplastic) can be used in composites depending on applications and the required specifications. Composites are used in several end-use industries, including aerospace & defense, automotive & transportation, wind energy, marine, pipe, tanks & pressure vessel, construction & infrastructure, and electronics.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200051282 

The Aerospace & Defense Industry is the second major end-use sector in the composites market due to decreased weight and increased fuel efficiency. In addition, more efficient structural and aerodynamic design is achieved due to a greater strength-to-weight ratio.  In developed countries, governmental focus on replacing old aircraft is driving the adoption of composite materials to meet regulatory standards set by aviation authorities. These materials offer significant advantages such as lightweight properties, high strength-to-weight ratios, and corrosion resistance, making them ideal for modernizing aging aircraft fleets. Regulatory bodies, such as the Federal Aviation Administration (FAA) in the United States and the European Union Aviation Safety Agency (EASA), enforce stringent safety and environmental standards

Prominent players include Owens Corning (US), Toray Industries, Inc. (Japan), Teijin Limited (Japan), Mitsubishi Chemical Holdings Corporation,(Japan), and SGL Group (Germany). These players have adopted various growth strategies to strengthen their position in the market. These include product launches, contracts, partnerships, mergers and acquisitions, and new product development activities to expand their presence in the composite market further.

Request Sample Pages: https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=200051282 

Toray Industries, Inc

 Toray Industries Inc. is a multinational corporation headquartered in Japan and is one of the largest manufacturers of industrial materials in the world. Toray has grown into a diversified company with operations spanning various sectors, including fibers and textiles, plastics and chemicals, IT-related products, carbon fiber composite materials, and life science products. Toray’s business encompasses a wide range of industries, including automotive, aerospace, electronics, healthcare, and environmental solutions. With a strong focus on innovation and sustainability, Toray is a leading producer of carbon fiber composite materials used in aerospace, automotive, and sporting goods industries, providing lightweight, high-strength solutions.Toray Industries, Inc.’s subsidiary, Zoltek Composites, Inc. (US) offers carbon composites for the automotive, maritime, commercial, and mobility industries. The company has manufacturing and research facilities in North America, Latin America, Europe, Africa, Asia, and other regions and operates in 29 countries. It has 283 subsidiaries, with 103 in Japan and 180 overseas.

Teijin Limited

Teijin Limited is a Japanese chemical, pharmaceutical, and information technology company involved in the manufacture, processing, and selling of chemical products. Its main fields of operations are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, product converting, and IT products. The company offers advanced solutions having applications in the transportation, electronics, energy, and healthcare sectors. Teijin has a wide geographical presence with manufacturing facilities in North America, Europe, and the Asia Pacific, covering over 20 countries.

Inquire Now: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=200051282 

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/composite-market-200051282.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Composites Market Size, Opportunities, Top Companies, Growth, Trends, Regional Analysis, Key Segments, and Forecast to 2028

AI Marketing Book Author Emanuel Rose to Keynote at Two Major Industry Events

AI Marketing Book Author Emanuel Rose to Keynote at Two Major Industry Events

“My goal with this book and my speaking engagements is to empower marketers to embrace AI not just as a technological tool, but as a catalyst for authentic connection and meaningful customer experiences,” Rose explains.
Emanuel Rose, author of the AI marketing book “Authentic Marketing in the Age of AI,” will keynote at the Digital Healthcare and Innovation Conference on September 12, 2024, and the PMI Montana-Wyoming Chapter’s Annual Meeting on September 27-28. He will discuss AI’s transformative role in marketing. Rose also hosts the “Marketing in the Age of AI” podcast, exploring AI marketing trends and practical advice.

Emanuel Rose, acclaimed author of the AI marketing book, “Authentic Marketing in the Age of AI” is set to deliver keynote presentations at two prominent industry events this fall, further cementing his status as a leader in the AI-powered marketing space.

Rose will share his expertise at the Digital Healthcare and Innovation Conference hosted by Eprenz on September 12, 2024, and at the PMI Montana-Wyoming Chapter’s 2024 Professional Development Day and Annual Meeting on September 27-28 in Missoula, Montana. His presentations will focus on the transformative power of AI in marketing, drawing from the wealth of knowledge presented in his AI marketing book.

“Authentic Marketing in the Age of AI,” published in 2023. has become an indispensable resource for marketers navigating the rapidly changing landscape of AI-driven strategies. The book provides a comprehensive overview of AI’s impact on marketing, from automating routine tasks to enhancing customer engagement and personalization. Rose offers practical guidance on selecting and implementing the right AI tools, measuring ROI, and ensuring ethical AI use. “My goal with this book and my speaking engagements is to empower marketers to embrace AI not just as a technological tool, but as a catalyst for authentic connection and meaningful customer experiences,” Rose explains.

In addition to his speaking engagements and AI marketing book, Rose recently launched the AI marketing podcast “Marketing in the Age of AI with Emanuel Rose” where he explores the latest trends, interviews industry leaders, and offers actionable advice for leveraging AI to achieve marketing success. The podcast is available on YouTube, Spotify, Apple Podcasts, and Amazon Music.

About Emanuel Rose:

Emanuel Rose is a CEO, author, speaker, and digital marketing expert with over three decades of experience. He is the founder of Strategic eMarketing, a successful digital marketing agency, and has authored several books on marketing and technology. Rose is a sought-after speaker known for his engaging presentations and practical insights.

About “Authentic Marketing in the Age of AI”

“Authentic Marketing in the Age of AI” is a comprehensive AI marketing book for marketers seeking to leverage the power of AI while maintaining brand authenticity and ethical practices. The book covers topics such as:

– Understanding the fundamentals of AI and its applications in marketing

– Leveraging AI tools for data analysis

– Content creation and campaign management

– Implementing AI-powered chatbots, recommendation engines, and automated ad platforms

– Strategies for integrating AI into existing marketing workflows

– Tips for maximizing ROI from AI marketing investments

– Case studies of successful AI marketing initiatives from leading brands

Media Contact
Company Name: Strategic eMarketing
Contact Person: Emanuel Rose
Email: Send Email
Phone: 707 506 6138
City: Reno
State: Nevada
Country: United States
Website: https://emanuelrose.com/

OurTopClinic Leads Telehealth Innovation, Making Quality Healthcare Accessible and Affordable

Focusing on compassionate, personalized care combined with cutting-edge technology, OurTopClinic delivers affordable healthcare solutions that cater to the uninsured and those seeking convenient care from the comfort of their homes. This innovative approach ensures that quality healthcare is accessible to everyone, regardless of their circumstances, redefining the delivery of medical services in today’s digital age.

OurTopClinic is making significant strides in the telehealth industry by providing an unmatched level of online medical consultation and urgent care. This innovative approach is making high-quality healthcare accessible from the comfort of one’s home. This approach is transforming how healthcare is delivered, ensuring it remains affordable and accessible, particularly for uninsured patients.

The clinic’s dedication to innovation is highlighted by its empowerment of nurse practitioners and the integration of advanced technology to provide a comprehensive range of online health services. “At OurTopClinic, we’re committed to caring for you like family, ensuring healthcare is always within your reach, wherever you are,” states the OurTopClinic Team.

What sets this telehealth provider apart is the variety of services offered and the compassionate care they deliver. Patients regularly commend the personalized attention they receive, which often exceeds what they have experienced in traditional in-person healthcare settings. One patient shared, “OurTopClinic was my best telehealth visit. While there are many telehealth platforms, OurTopClinic stood out for its compassion. The provider took their time during our session, ensuring I felt heard and valued.”

OurTopClinic is particularly noted for making healthcare more inclusive by enhancing the roles of nurse practitioners and offering flexible service options that cater to a wide array of patient needs. This approach not only improves the efficiency of healthcare delivery but also ensures that each patient feels cared for personally.

With an online membership available for as low as $14.99 per month, patients can enjoy reduced rates for virtual visits, access reserved appointment slots during fully booked periods, and benefit from a 24/7 health hotline, providing peace of mind and immediate access to medical professionals.

OurTopClinic offers an easy and effective gateway for those considering a shift to telehealth. With services covering everything from urgent care to mental health and weight loss consultations and a user-friendly platform that allows easy booking of appointments, OurTopClinic is making it easier than ever to manage health online.

OurTopClinic invites prospective patients to visit their website to explore the services offered and book an appointment.

Media Contact
Company Name: Ourtopclinic
Contact Person: Naurah Gaspard
Email: Send Email
Country: United States
Website: https://ourtopclinic.com

Digital Oilfield Market to Grow at a CAGR of 4.9% by 2031 Driven by Rising Demand for Enhanced Safety Measures

“Skyquest Technology”
Digital Oilfield Market Size, Share, Growth Analysis, By Process(Production Optimization, Drilling Optimization, Reservoir Optimization, Safety management), By Solution(Hardware Solutions, Software & Service Solutions, and Data Storage Solutions), By Process(Production Optimization, Drilling Optimization, Reservoir Optimization, Safety management and Others), By Application(Onshore, and Offshore), By Region – Industry Forecast 2024-2031

Digital Oilfield Market size was valued at USD 35.25 billion in 2022 and is poised to grow from USD 36.98 billion in 2023 to USD 54.22 billion by 2031, at a CAGR of 4.9% during the forecast period (2024-2031).

The growing trend of digitalization across a wide range of industries, including oil and gas, is a primary driver of the digital oilfield market. The rise in demand for oil and oil products across multiple industries, along with the possibly hazardous working conditions of the oil and gas industry, has boosted the demand for digital oilfields. In addition, since several oilfields have become saturated, digital approaches are being applied to increase oil recovery. Financial expenses and time consumed for operations have immensely reduced because digital technologies have entered every aspect of operations, from exploration to production. These technical advancements have increased the efficiency of operations. Today the operators can also successfully meet their net-zero commitments with the help of an emission monitoring system.

Download a detailed overview:

https://www.skyquestt.com/sample-request/digital-oilfield-market 

Digital Intelligence Enhancing the Operations of the Oil & Gas Sector 

A rising percentage of unconventional oil and gas reserves, along with declining production from existing wells, are driving demand for digitization in the oilfields. Digital oilfield technologies also provide remote monitoring and automated operations from a central location, cutting total operational costs. The popularity of IoT sensors, advanced analytics, and automation is increasingly in various fields like hardware, software, and services. Now, oilfield operators can make data-based decisions because such advanced technologies have helped in real-time monitoring. 

Immense Competition in the Oilfield Markets is Encouraging Companies have to Invest in Digital Technology 

In recent times, it has become crucial for the oilfield companies to invest in digital technologies as it has completely captured the industry. The reservoir and drilling segments are also seeing immense improvement because of better reservoir operation, cheap drilling, and security from drilling accidents. To maintain market dominance in this competitive energy environment the key market players are relying on digital transformation

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/digital-oilfield-market 

  • January 10, 2024 saw SLB partner with Geminus AI. SLB has exclusive access to a cutting-edge AI model builder for oil and gas projects through an investment and technology arrangement. It will also use modern physics techniques. The Geminus model builder uses physics-based methods to process data to create precise AI models. These models are cost-effective and efficient for large-scale deployment compared to traditional AI systems.
  • At the Abu Dhabi International Petroleum Exhibition and Conference, Halliburton Company showcased green technology. The event took place October 2-5, 2023. The company offers cutting-edge drilling, completions, and production technology in its latest products. It features breakthrough AI applications. Their technology offers clients enhanced wellbore stability, drilling precision, and well monitoring capabilities.
  • Halliburton and PTT Exploration and Production Public Company Limited (PTTEP) have signed an MoU. This MoU aims to develop and commercialize digital transformation solutions for the energy sector in Thailand, Malaysia, and Vietnam. Under the arrangement, the two companies would create and sell innovative digital products. It will improve operational efficiency and productivity while solving energy industry concerns. PTTEP offers the Well Delivery Process (WDP) and Advanced Production Excellence. These solutions are based on Halliburton’s Decision Space 365 product suite.
  • On June 19, 2023, Halliburton Company and Nabors Industries signed a deal on pioneering well-construction automation systems. Under the terms of the agreement, Halliburton and Nabors will work together on technologies such as the Halliburton Well Construction 4.0 digital surface and subsurface drilling technologies, the LOGIX Autonomous Drilling Platform, the Nabors SmartROS universal rig controls and automation platform, and the RigCLOUD high-performance digital infrastructure platform.

 

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/digital-oilfield-market 

The usage of digital intelligence has simplified the decision-making process in this sector. To fulfill product, demand an effective production process using cost-effective approaches is required. Digitalization significantly reduces operational risk and improves the safety of workers. The utilization of technology in the oilfield market improves the industry’s operational performance. The oil and gas industry are delighted with its investment in digital technology to reduce expenses across every operation. Digital oilfield technologies will ultimately benefit both field workers and engineers.

Related Reports:

Blockchain Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/digital-oilfield-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Digital Oilfield Market to Grow at a CAGR of 4.9% by 2031 Driven by Rising Demand for Enhanced Safety Measures

Cutaneous Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Cutaneous Squamous Cell Carcinoma Pipeline Insight, 2024” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Cutaneous Squamous Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Cutaneous Squamous Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Cutaneous Squamous Cell Carcinoma Pipeline Outlook

Key Takeaways from the Cutaneous Squamous Cell Carcinoma Pipeline Report

  • June 2024:- Incyte Corporation- A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Squamous Cell Carcinoma. This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous Squamous Cell Carcinoma.
  • June 2024:- Merck Sharp & Dohme LLC- A Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MK-3475A in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC.
  • DelveInsight’s Cutaneous Squamous Cell Carcinoma pipeline report depicts a robust space with 45+ active players working to develop 45+ pipeline therapies for Cutaneous Squamous Cell Carcinoma treatment.
  • The leading Cutaneous Squamous Cell Carcinoma Companies such as Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.
  • Promising Cutaneous Squamous Cell Carcinoma Therapies such as MK-3475A, L19IL2 +L19TNF, Cemiplimab, Everolimus, Sirolimus, and others.

Stay informed about the cutting-edge advancements in Cutaneous Squamous Cell Carcinoma Treatments. Download for updates and be a part of the revolution in oncology care @ Cutaneous Squamous Cell Carcinoma Clinical Trials Assessment

Cutaneous Squamous Cell Carcinoma Emerging Drugs

HLX 07: Shanghai Henlius Biotech

HLX07 is a bio-better independently developed by Henlius. Adopting the self-developed advanced antibody engineering platform, Henlius re-engineered cetuximab by humanizing its Fab regions and minimizing its glycan contents to generate HLX07 to reduce the immunogenicity and increase the affinity of the product. Pre-clinical studies have shown that HLX07 binds EGFR with similar affinity and had better bioactivity compared to cetuximab. Henlius holds patents of HLX07 in several jurisdictions including China, the United States, the European Union, Australia, and Japan. Moreover, Henlius has received clinical trial approvals for HLX07 in the treatment of solid tumors in Chinese mainland, the United States, and Taiwan China. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.

Opzelura: Incyte Corporation

Opzelura, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is the first and only topical JAK inhibitor approved for use in the United States for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.

RM 1995: Rakuten Medical

RM-1995, developed by Rakuten Medical using its IlluminoxTM platform, is an antibody-dye conjugate comprised of a monoclonal antibody specific for cell-surface interleukin 2 (IL-2) receptor α-chain (CD25) and IRDye® 700DX (IR700), a light-activatable dye. RM-1995 photo immunotherapy is designed to specifically kill CD25+ regulatory T cells (Tregs) within solid tumors, once illuminated with 690nm nonthermal red light. Rakuten Medical’s preclinical data has suggested that RM-1995 photo immunotherapy treatment can be utilized to specifically deplete intratumoral Tregs, thereby alleviating local Treg-mediated restraint within the tumor microenvironment, rapidly improving the CD8 T cell: Treg ratio, and reinvigorating effector CD8+ T cell responses. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Cutaneous Squamous Cell Carcinoma.

Learn more about Cutaneous Squamous Cell Carcinoma Drugs opportunities in our groundbreaking Cutaneous Squamous Cell Carcinoma Research and development projects @ Cutaneous Squamous Cell Carcinoma Unmet Needs

Cutaneous Squamous Cell Carcinoma Companies

Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.

Cutaneous Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Cutaneous Squamous Cell Carcinoma Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Discover the latest advancements in Cutaneous Squamous Cell Carcinoma Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology disease @ Cutaneous Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Cutaneous Squamous Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Cutaneous Squamous Cell Carcinoma Companies- Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, I-MAB Biopharma, Roche, Genexine, CureVac, and others.
  • Cutaneous Squamous Cell Carcinoma Therapies – MK-3475A, L19IL2 +L19TNF, Cemiplimab, Everolimus, Sirolimus, and others.
  • Cutaneous Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Cutaneous Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Cutaneous Squamous Cell Carcinoma Pipeline on our website @ Cutaneous Squamous Cell Carcinoma Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Cutaneous Squamous Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Cutaneous Squamous Cell Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug Name : Company Name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. HLX 07: Shanghai Henlius Biotech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. RM 1995: Rakuten Medical
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Cutaneous Squamous Cell Carcinoma Key Companies
  21. Cutaneous Squamous Cell Carcinoma Key Products
  22. Cutaneous Squamous Cell Carcinoma- Unmet Needs
  23. Cutaneous Squamous Cell Carcinoma- Market Drivers and Barriers
  24. Cutaneous Squamous Cell Carcinoma- Future Perspectives and Conclusion
  25. Cutaneous Squamous Cell Carcinoma Analyst Views
  26. Cutaneous Squamous Cell Carcinoma Key Companies
  27. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cutaneous Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight